FDA/Industry Interactions Might Get Revised Rules Of Road After Opioid Publicity

Sen. Manchin calls for congressional investigation of “pay to play” allegations; FDA maintains the meetings with industry were for scientific, not regulatory purposes, but the agency is looking into the matter.